Breast cancer remains a significant health challenge in Canada, necessitating the continued exploration of novel therapeutic strategies. This thesis investigates the role of two key players, Zinc Finger E-box Binding Homeobox 2 (ZEB2 transcription factor) and Interleukin-7 Receptor (IL-7R), in breast cancer progression and therapeutic response. We sought to unravel the intricate interplay between these proteins and their roles in breast cancer biology. Utilizing the DEPMAP (Dependency Map) database, a comprehensive resource that provides information on gene essentiality and drug responses across various cancer cell lines, we identified ZEB2 and IL-7R as potential therapeutic targets in breast cancer. Subsequent validation experiments confirmed their overexpression in breast cancer cell lines, highlighting their potential as prognostic indicators and therapeutic targets. Immunofluorescent imaging and enzyme-linked immunosorbent assays (ELISA) revealed intriguing insights into the intracellular localization of IL-7R and the autocrine/intracrine signaling potential in breast cancer cells. Functional assays demonstrated the pro-proliferative and pro-migratory effects of IL-7 stimulation in breast cancer cells. Additionally, our investigation into downstream signaling pathways unveiled the activation of the Phosphoinositide 3-kinase/Protein Kinase B (PI3K/AKT) pathway upon IL-7 stimulation, suggesting potential therapeutic avenues for targeting this pathway in breast cancer treatment. In vitro drug combination studies revealed promising synergistic effects between Lysine- Specific Demethylase 1 (LSD1) and AKT inhibitors in ZEB2High IL-7RHigh breast cancer cells. While our findings present promising avenues for breast cancer treatment, further research is warranted. Ultimately, this thesis contributes to the growing body of knowledge aimed at advancing precision medicine approaches for breast cancer treatment.